{
  "scenario_id": "healthcare_genomics_research_investment_2025",
  "context": "Biopharmaceutical company evaluating major investment in genomics research for personalized medicine platform",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "CFO",
      "Board of Directors"
    ],
    "influencers": [
      "Head of R&D",
      "Chief Medical Officer",
      "VP Business Development",
      "Key Opinion Leaders",
      "Regulatory Experts"
    ]
  },
  "request": {
    "amount": "$200 million",
    "purpose": "Build comprehensive genomics research platform for drug discovery and personalized medicine development",
    "urgency": "medium",
    "justification": "Genomics represents the future of medicine with potential to revolutionize drug development and patient outcomes"
  },
  "decision_process": [
    {
      "stage": "scientific_feasibility",
      "duration": "8 weeks",
      "activities": [
        "Technology landscape assessment",
        "Scientific advisory board consultations",
        "IP portfolio evaluation"
      ],
      "outcome": "Strong scientific foundation with clear path to clinical applications"
    },
    {
      "stage": "market_analysis",
      "duration": "6 weeks",
      "activities": [
        "Market size projections",
        "Competitive landscape analysis",
        "Reimbursement pathway assessment"
      ],
      "outcome": "Attractive market opportunity with $50B+ addressable market by 2030"
    },
    {
      "stage": "financial_modeling",
      "duration": "4 weeks",
      "activities": [
        "NPV analysis",
        "Sensitivity testing",
        "Funding strategy development"
      ],
      "outcome": "Positive NPV with attractive risk-adjusted returns"
    },
    {
      "stage": "strategic_alignment",
      "duration": "3 weeks",
      "activities": [
        "Portfolio fit assessment",
        "Synergy evaluation",
        "Strategic priority alignment"
      ],
      "outcome": "Excellent strategic fit with existing capabilities and pipeline"
    },
    {
      "stage": "risk_assessment",
      "duration": "2 weeks",
      "activities": [
        "Technical risk evaluation",
        "Regulatory risk analysis",
        "Execution risk assessment"
      ],
      "outcome": "Manageable risk profile with clear mitigation strategies"
    }
  ],
  "business_impact": {
    "expected_benefits": [
      "Accelerated drug discovery",
      "Personalized medicine leadership",
      "New revenue streams",
      "Scientific reputation enhancement"
    ],
    "projected_revenue": "$2 billion in new product revenue over 10 years",
    "risk_factors": [
      "Technology development delays",
      "Regulatory hurdles",
      "Data privacy concerns",
      "Market adoption challenges"
    ]
  },
  "outcome": "Approved",
  "implementation_timeline": {
    "start_date": "2024-01-01",
    "completion_date": "2028-12-31",
    "milestones": [
      "Phase 1 - Infrastructure setup: 2024-01-01 to 2024-06-30",
      "Phase 2 - Initial research programs: 2024-07-01 to 2025-12-31",
      "Phase 3 - Clinical applications: 2026-01-01 to 2028-12-31"
    ]
  },
  "outcome_tracking": {
    "6_month_review": "Infrastructure deployment on track, 3 research partnerships established, regulatory pathway mapping completed",
    "12_month_review": "First genomic analysis platform operational, 2 drug discovery programs initiated, $50M in milestone payments received",
    "actual_roi": "Project tracking 18% ROI (vs projected 15%) with accelerated regulatory approvals"
  },
  "lessons_learned": "Early regulatory engagement crucial for genomics research - investment in compliance team 40% higher than budgeted but essential for market access. Technology integration more complex than anticipated, requiring additional bioinformatics expertise."
}